Table 1 Types of HLA that are involved in the susceptibility or severity of COVID-19
From: The role of HLA genotypes in understanding the pathogenesis of severe COVID-19
Authors (ref) | Year | Locality | People/ Database | HLA variants | Trait |
|---|---|---|---|---|---|
Abdelhafiz et al. [56] | 2022 | Egypt | 69 people with COVID-19/ mild/ moderate/ severe | HLA-B*15 | Protective |
Yung et al. [47] | 2021 | Hong Kong | 190 people with COVID-19/ 3892 healthy controls | HLA-B*22 | Susceptibility |
Shkurnikov et al. [57] | 2021 | Moscow, Russia | 111 people with COVID-19/ 428 healthy controls | HLA-A*02:01 HLA-A*03:01 HLA-A*01:01 | Protective Protective Susceptibility |
Anzurez et al. [58] | 2021 | Japan | 30 mild, 75 moderate, 51 Severe and 22 Critical COVID-19 | HLA- DRB1*09:01 | Susceptibility |
Weiner et al. [59] | 2021 | 4 Countries (Germany, Spain, Switzerland and the United States) | 435 people with COVID-19 | HLA-C*04:01 | Susceptibility |
Langton et al. [60] | 2021 | North East of England | 147 people with COVID-19/ 8514 healthy controls/ IRAS project 283,409; REC reference: 20/YH/0184 | HLA-DRB1*04:01 HLA-DRB1*01:01 | Protective Protective |
Romero Lopez et al. [61] | 2021 | 28 states of Mexico | TepiTool server from the IEDB Analysis Resource database/ Total: 71,099 | HLA-DRB1*01 | Susceptibility |
L Warren et al. [62] | 2021 | New York cohort | 100 people with COVID-19/ 26 healthy controls | HLA-DPA1*02:02 HLA-C*04:01 HLA- A*11:01 | Susceptibility Severity severity |
M A Naemi et al. [33] | 2021 | South Asia (Bangladeshis, Indians, and Pakistanis) | 64 mild, 31 severe and 20 fatal COVID-19 | HLA-B*51 HLA-B*35 | Susceptibility Protective |
Sakuraba et al. [54] | 2020 | 74 countries | The Allele Frequency Net Database and worldometer.info | HLA-C*05 | Susceptibility |
Novelli et al. [50] | 2020 | Italy | 99 severe or extremely severe COVID-19/ 1017 healthy controls | HLA-B*27:07 | Susceptibility |
Wang et al. [63] | 2020 | China/ Han people | 82 people with COVID-19/3548 healthy controls | HLA-C*07:29 HLA-B*15:27 | Susceptibility Susceptibility |
Lorente et al. [64] | 2020 | Spain/ Canary Islands | 72 severe COVID-19/ 3886 healthy controls | HLA-B*39 HLA-C*16 | Susceptibility Susceptibility |
Correale et al. [65] | 2020 | Italy (different regions) | Italian Bone Marrow Donors Registry (IBMDR) high-definition-analysis database | HLA-B*44 HLA-C*01 | Susceptibility Susceptibility |
Pisanti et al. [49] | 2020 | Italy | IBMDR high-definition-analysis database | HLA-A*01:01 HLA-B*08:01 HLA-C*07:01 HLA-DRB1*030:1 | Susceptibility Susceptibility Susceptibility Susceptibility |
Warren et al. [1] | 2020 | China/ Wuhan | 5 patients with COVID-19 | HLA-A*24:02 | Susceptibility |
Tomita et al. [37] | 2020 | 19 Countries | (Allele Frequency Net Database)/ An in silico analysis | HLA-A*02:01 HLA-A*24:02 HLA-A*11:01 | Susceptibility Protective protective |
Toyoshima et al. [39] | 2020 | 28 countries | 12,343 SARS-CoV-2 genome sequences isolated from patients/the reference SARS-CoV-2 sequence | HLA-A*11:01 | protective |
Lorente et al. [64] | 2020 | Spain/ Canary Islands | 72 severe COVID-19/ 3886 healthy controls | HLA-A*32 | protective |
Iturrieta et al. [28] | 2020 | Spain | 5 mild, 20 moderate and 20 severe COVID-19 | HLA-B*15:03 | protective |
Pisanti et al. [49] | 2020 | Italy | IBMDR high-definition-analysis database | HLA-A*02:01 HLA-B*18:01 HLA-C*07:01 | Protective protective protective |
Littera et al. [66] | 2020 | Sardinian | 182 SARS-CoV-2 patients/619 healthy controls | HLA-A*02:05 HLA-B*58:01 HLA-C*07:01 | Protective Protective protective |